CSL signs licensing deal with Eli Lilly for clazakizumab
Tweet
Share
E-mail
FILE PHOTO: A drone view shows the Eli Lilly logo on one of the company’s offices in San Diego, California, U.S., November 21, 2025. REUTERS/Mike Blake/File Photo
(Removes incorrect reference to a kidney disease treatment deal from the headline)
Feb 18 (Reuters) - Australia's CSL said on Wednesday it had entered into an exclusive licensing agreement with Eli Lilly and Co, granting it certain rights to develop and commercialise clazakizumab, an antibody aimed at preventing heart-related illness and death in people with end‑stage kidney disease.
(Reporting by Shivangi Lahiri in Bengaluru; Editing by Maju Samuel)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Guatemala says 2,300 Mexicans deported from US entered in 2026
- US employer healthcare costs set to rise 9.5% in 2027, Aon says
- China exports to US rise of rare earth critical to aerospace sector
Create E-mail Alert Related Categories
ReutersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
